ClinicalTrials.gov
ClinicalTrials.gov Menu

An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01201980
Recruitment Status : Completed
First Posted : September 15, 2010
Last Update Posted : January 10, 2012
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This study is aimed to evaluate response rate of the antihypertensive treatment with a calcium antagonist in real life practice, to evaluate patients' quality of life and to collect the following Serbia-specific epidemiology data on hypertension: demographic data, patents characteristics, and patients' management/treatment.

Condition or disease
Hypertension

Study Type : Observational
Actual Enrollment : 300 participants
Time Perspective: Prospective
Official Title: An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension and to Evaluate Patients' Quality of Life
Study Start Date : December 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Group/Cohort
1
Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist



Primary Outcome Measures :
  1. To evaluate proportion of patients on antihypertensive pharmacological treatment reaching SBP goals according to the ESC 2007 guidelines (<140 mmHg*). [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. To evaluate proportion of patients on antihypertensive pharmacological treatment reaching DBP goals according to the ESC 2007 guidelines (<90 mmHg*). [ Time Frame: 24 weeks ]
  2. To collect local epidemiological date on patients with hypertension (demographic data; hypertension management data: treatment, treatment changes and tolerability data). [ Time Frame: 24 weeks ]
  3. To evaluate patients quality of life after 12 and 24 weeks by using patients quality of life questionnaire [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Speciality care clinics
Criteria

Inclusion Criteria:

  • Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01201980


Locations
Serbia
Research Site
Belgrade, Serbia
Research Site
Cacak, Serbia
Research Site
Kragujevac, Serbia
Research Site
Niska Banja, Serbia
Research Site
Nis, Serbia
Research Site
Pancevo, Serbia
Research Site
Sabac, Serbia
Research Site
Sremska Kamenica, Serbia
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: prof. dr Zorana Vasiljevic Clinical Center of Serbia, Belgrade

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01201980     History of Changes
Other Study ID Numbers: NIS-CRS-DUM-2010/2
First Posted: September 15, 2010    Key Record Dates
Last Update Posted: January 10, 2012
Last Verified: January 2012

Keywords provided by AstraZeneca:
essential arterial hypertension
calcium antagonist

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases